TrialAntimicrobial agents and chemotherapy2024

Patient outcomes by baseline pathogen resistance phenotype and genotype in CERTAIN-1, a Phase 3 study of cefepime-taniborbactam versus meropenem in adults with complicated urinary tract infection.

Greg Moeck et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.